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Introduction
Few topics in nephrology have been the subject of so 
many randomized controlled trials (RCTs), meta-analyses 
and reviews than that of extracorporeal renal replacement 
in acute kidney injury (AKI). Since the introduction of 
hemodialysis as a valid treatment for renal failure by Kolﬀ  
in the early 1940s [1], intermittent renal replacement 
therapy (IRRT) was oﬀ ered as a bridge until recovery of 
kidney function; ﬁ rst in a low-eﬃ  cient and therefore 
protracted version, later becoming progressively shorter. 
In the 1980s, Kramer and colleagues introduced con tinu-
ous renal replacement therapy (CRRT) as an alternative, 
allowing blood puriﬁ cation 24 hours per day – at least in 
principle [2].
CRRT originally applied a simple concept without 
pumps or technology (continuous arteriovenous hemo-
ﬁ ltration). Since this approach often lacked eﬃ  ciency, 
however, machines containing blood pumps soon made 
their appearance (continuous venovenous hemoﬁ ltra-
tion). Whereas solute removal with IRRT at the origin 
essen tially made use of diﬀ usion – that is, gradient-
related molecule shifts in a liquid milieu from higher to 
lower concentration gradients – CRRT started as a con-
vective strategy, driven by removal of solute-containing 
ultraﬁ ltrate through large pores and its replacement by 
substitution ﬂ uid. With time, diﬀ usion was also implied 
in CRRT by introducing additional pumps to the 
machines, while convective strategies became more 
widely applied in IRRT. Characteristics of CRRT and 
IRRT tended to con verge further at the beginning of this 
century in a concept named sustained low-eﬃ  ciency 
daily dialysis (SLEDD) [3], by applying IRRT mostly at 
lower blood and dialysate ﬂ ows but at prolonged dialysis 
times. Th e term low eﬃ  ciency is, however, in many cases 
a misnomer [4,5]. Sometimes, this strategy is also named 
prolonged inter mittent renal replacement therapy.
It is diﬃ  cult to ﬁ nd a uniform deﬁ nition of SLEDD in 
the literature. In fact, one of the advantages of SLEDD 
lies in its ﬂ exibility both in terms of duration and of 
intensity. In the present text, the term SLEDD refers to 
any hemodialysis treatment performed with conventional 
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dialysis machines over a longer time lapse than traditional 
intermittent hemodialysis (usually ≥5 hours).
Already from the early days, the question was raised 
regarding which of CRRT or IRTT was related to better 
outcome. Th e general perception was that the continuous 
approach, due to its slow protracted nature, would result 
in better outcomes. At least seven published RCTs and 
three meta-analyses, however, were unable to demon-
strate a diﬀ erence in outcome between both approaches 
[6-15], with a reported relative risk of 0.99 in the most 
recent meta-analysis [15].
Some authors have pointed to ﬂ aws in the design of 
these RCTs [15]. Several of these biases were logistic, 
however, and in that case inherent to the very nature of 
the strategies implied [16] – such as the incapacity to 
enroll patients into continuous protocol arms due to 
unavailability of appropriate devices [10], or the impossi-
bility to reach the preset exchange volume [11]. Logistical 
factors should thus also be taken into account when 
deciding on CRRT or IRRT [16]. Other biases skewing 
these RCTs are related to study design, conduct and 
reporting ﬂ aws.
In speciﬁ c subpopulations and/or based on arguments 
other than outcome, however, one of these two 
approaches might still be preferable over the other. In the 
present pro/con debate, both the advantages and 
disadvantages of CRRT and IRRT will be reviewed.
Of note, all therapeutic strategies available should not 
be considered as competitors, but rather as alternatives, 
each of which might be applicable within the same unit 
and even the same patient, depending on the practical 
options at hand at a given moment and on the metabolic 
or the ﬂ uid balance needs of the patient.
Pro continuous renal replacement therapy
Several theoretical advantages have been attributed to 
CRRT over IRRT: more hemodynamic stability allowing 
more adequate ﬂ uid removal; better recovery of renal 
function; and more eﬃ  cient removal of small and large 
metabolites. None of these assumptions, however, could 
consistently withstand the test of controlled clinical trial 
conditions.
Hemodynamic stability and fl uid removal
Several controlled trials fail to consistently demonstrate 
better hemodynamic stability and/or superior vital para-
meters for CRRT [6,7,10-12,17]. In a meta-analysis from 
the Cochrane group published in 2007, mean arterial 
pressure was the only clinical hemodynamic parameter 
that was signiﬁ cantly higher with CRRT than with IRRT; 
the number of hypotension episodes was not diﬀ erent, 
however [14]. Another systematic review showed no 
nominal diﬀ erences [13]. A third review found a 
suggestion that CRRT was superior with regard to 
episodes of hemodynamic instability (P = 0.03) [15], 
based on four studies – with the major eﬀ ect coming 
from the study by Augustine and colleagues, in which the 
diﬀ erence between both strategies was signiﬁ cant but the 
fall in mean arterial pressure amounted to only 
2.6 mmHg versus the start of treatment [6].
Overall, it can be concluded that if there is a hemo-
dynamic beneﬁ t for CRRT, this nevertheless is not 
translated into diﬀ erences of survival. Data also seem to 
suggest that part of the observed hemodynamic advan-
tages of CRRT could be attributed to heat loss and hypo-
thermia [12], improving venous return and blood 
pressure [18]. A similar eﬀ ect can be obtained in IRRT by 
cooling dialysate, which has now become current practice 
in chronic hemodialysis [19] but applies to the AKI 
setting as well.
One problem potentially blurring the results of RCTs 
comparing CRRT and IRRT is the reluctance for includ-
ing patients with major hemodynamic problems out of 
fear of instability in case of randomization to intermittent 
dialysis; this might result in the exclusion of the most 
unstable patients, reducing the diﬀ erences among therapies.
A protracted treatment should allow removing ﬂ uid at 
a larger cumulative volume. CRRT allowed markedly 
more negative ﬂ uid balances in one RCT [6] but not in 
another [12].
In view of all of the uncertainties mentioned above and 
because of the physiological plausibility, ﬂ uid-overloaded 
patients are among those with the highest potential to 
beneﬁ t from CRRT or from IRRT in the SLEDD mode. 
CRRT has also been suggested to oﬀ er more possibilities 
for the administration of parenteral nutrition ﬂ uids [20] – 
a suggestion, however, not conﬁ rmed in a prospective 
study [10].
Preservation of renal function
One of the major potential advantages of preserving 
hemo dynamic stability is a positive eﬀ ect on recovery of 
kidney function. When autoregulation is lost due to AKI, 
each new hypotensive episode decreases glomerular 
perfusion [21], causing recurrent focal ischemic injury 
and postponing recovery of kidney function according to 
some studies [22]. Each condition such as IRRT causing 
more hypotension might thus theoretically emanate in a 
slower recovery of kidney function and a larger number 
of renal deaths (nonrecovery of renal function resulting 
in chronic dialysis), and might also aﬀ ect perfusion of 
other organ systems, such as the heart. Nevertheless, all 
controlled studies [6,8-11] and meta-analyses [13,14,23] 
devoted to this aspect failed to demonstrate superiority 
of CRRT in this regard. For the sake of completeness, 
three observational trials suggested less evolution into 
chronic kidney disease stage 5 on dialysis (formerly end-
stage renal disease) with CRRT [24-26]. In view of the 
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lack of a diﬀ erence in ﬁ ve RCTs and three systematic 
reviews [6,8-11,13,14,23], however, the evidence base 
oﬀ ered by these uncontrolled trials is insuﬃ  cient to 
overrule the controlled data.
Solute removal
Prolonging dialysis, even if dialyzer blood ﬂ ow and dialy-
sate ﬂ ow are decreased proportionally, promotes solute 
removal due to better mobilization from extra-plasmatic 
compartments [4]. In line with these ﬁ ndings, it has been 
suggested that slow strategies result in more eﬃ  cient 
removal.
A mathematical study compared the possibilities of 
removing the small solute urea with CRRT and IRRT. 
With CRRT, the threshold urea concentration could be 
maintained by increasing the ﬂ uid exchange volume in 
patients of all body weights up to a volume of more than 
45 l/day. For IRRT, it became impossible to reach the 
lowest threshold (blood urea nitrogen 60 mg/dl) for a 
body weight in excess of 90 kg [27] but the treatment 
time was not allowed to exceed 4 hours per day in spite of 
blood ﬂ ows of only 200 ml/minute. Of note, the way the 
modalities were introduced in the calculations (high 
volume for CRRT vs. a ﬁ xed limitation to 4 hours and an 
intermediate blood ﬂ ow for IRRT) is more important for 
the result than the modality per se: for IRRT, the target 
could easily have been reached by assuming longer treat-
ment times and/or higher blood ﬂ ows.
Real-life comparisons of small molecule removal are 
scarce. In one study, day-by-day urea and creatinine levels 
were lower with CRRT than IRRT [9]. In other studies, 
daily urea clearances or concentrations were the same with 
both approaches [10,11]; while in a third study, only 
creatinine and not urea decreased more with CRRT [12].
Removal of cytokines might be more clinically relevant 
than removal of urea or creatinine in a population that is 
in general very sick and inﬂ amed. At least two studies 
conﬁ rmed this cytokine removal by CRRT, by adsorption 
on the mem brane, and/or by transmembrane elimination 
[28,29]. In one study, TNFα could be found in the ultra-
ﬁ ltrate, but there was no signiﬁ cant decrease in plasma 
concentration for this compound, as well as for all nine 
other cytokines or cytokine receptors under consideration 
[28]. In another study, removal was rapidly overwhelmed 
by generation once the membrane surfaces were 
saturated – and removal aﬀ ected proinﬂ ammatory 
cytokines as much as their anti-inﬂ ammatory soluble 
receptors or antagonists [29]. It is conceivable that the 
same risk of indiscriminating removal applies also to 
anti-inﬂ ammatory cytokines such as IL-4, IL-10 or 1L-18. 
In addition, since removal is essentially by adsorption, 
ﬁ lters need to be changed regularly, increasing the cost 
and decreasing the continuity of the treatment. Of note, 
removal of cytokines and other large molecules can be 
obtained just as well, if not better, with IRRT or SLEDD, 
under the condition that open membranes with large 
pore size (so-called high-ﬂ ux membranes) are applied.
Th e impact of increasing solute removal above 
currently applied levels can be questioned, as at least two 
large multicenter studies [30,31] and one meta-analysis 
[32] failed to demonstrate a survival advantage of more 
eﬃ  cient removal over standard removal. A potential 
reason for this failure could be that the higher intensity of 
solute removal also has a downside, such as greater 
removal of drugs resulting in inadequate drug concen tra-
tions (for example, of antimicrobials) or more electrolyte 
disturbances [11].
One factor negatively aﬀ ecting removal with CRRT is 
the frequent necessity to interrupt the procedure – for 
example, because of ﬁ lter clotting, which occurs more 
frequently in CRRT than in IRRT. Average delivery of 
treatment per day with CRRT was reported to be only 
19.5 hours [3,33], with observed individual values as low 
as 13.4 hours per day [3].
Specifi c patient populations benefi ting from CRRT
Although the evidence is contradictory (see above), the 
application of CRRT in combating severe ﬂ uid overload 
can be defended. Other speciﬁ c conditions in which 
CRRT has been proposed as the preferred option are 
combined acute renal and hepatic failure because of a 
bene ﬁ cial impact on cardiovascular stability and intra-
cranial pressure [34,35], and acute brain injury because 
of prevention of cerebral edema [36].
Peritoneal dialysis
Peritoneal dialysis is an often neglected continuous 
modality in AKI, although it can especially be of help in 
hemodynamically unstable and fragile patients, in those 
with enhanced bleeding risk, and in children [37], 
especially neonates and small children with postcardiac 
surgery AKI and hemolytic uremic syndrome. Of note, 
up to now only two RCTs have compared peritoneal 
dialysis with hemodialysis or related strategies in AKI. In 
a Vietnamese study on infected patients, continuous 
hemo ﬁ ltration was superior – but the applied peritoneal 
dialysis strategy was not comparable with what is 
currently state of the art [38]. Th e other study, in a 
supplement issue, showed no diﬀ erences [37] – here also, 
the peritoneal dialysis regime was unlikely to be suﬃ  cient 
to obtain satisfactory solute clearance.
Pro intermittent renal replacement therapy
From the above, it appears that very few arguments based 
on controlled clinical studies suggest superiority of CRRT 
above IRRT or vice versa. Except for a number of speciﬁ c 
indications, each one of these two strategies as well as 
any intermediate possibility lying in between (that is, 
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SLEDD in all its forms – see below) can clinically speak-
ing be considered a valid option for dialysis treatment of 
the average patient with AKI [16].
When the arguments in favor of IRRT are to be 
summed up, therefore, one might consider practical ele-
ments such as user-friendliness or limitation of expenses, 
as much as clinical factors beneﬁ ting its use in speciﬁ c 
subpopulations. Consequently, the following beneﬁ ts of 
IRRT will be discussed: practicality and ﬂ exibility of 
application; limitation of expenses; restriction of bleeding 
complications; and small solute removal in acute life-
threatening conditions.
Practicality and fl exibility of application
IRRT can be performed with the same technical infra-
structure as that available in the unit for chronic 
intermittent hemodialysis, allowing more ﬂ exibility for 
the treatment of the unpredictable and ever-ﬂ uctuating 
number of AKI patients in need of dialysis [16]. Th is 
approach also allows treatment of several patients per 
day with the same device, in contrast to CRRT where one 
dedicated device is to be attributed to each single patient. 
IRRT also allows more liberty for patient care and 
investigations outside the treatment and monitoring unit, 
by oﬀ ering a dialysis-free period, without loss of dialysis 
time or adequacy. Th e extra free time also oﬀ ers oppor-
tunities to mobilize the patients during their time oﬀ 
dialysis, in contrast to more continuous strategies 
whereby the relative immobilization may result in more 
severe muscle wasting and a higher risk of nosocomial 
respiratory tract infections.
IRRT has also another advantage: machines can be 
used in an extended protracted mode when needed, and 
the treatment time can be decreased coupled to an 
increase in eﬃ  cacy when the condition of the patient 
improves. Th is contrasts with CRRT machines, which do 
not allow an increase of the intensity of the treatment to 
allow shorter treatments.
Limitation of expenses
Th ere is an increasing trend to take cost into account for 
clinical therapeutic decisions. Th is is more the case, if, as 
concluded from the data above, a clear distinction based 
on outcome studies is diﬃ  cult.
In some early clinical trials in which cost estimation 
was not the main purpose, little diﬀ erence in expense was 
demonstrated [9,39]. More recently, several speciﬁ c cost 
analyses have been developed [33,40-43]. Most of these 
studies were limited to one single center or a few centers, 
and in all of them IRRT was less costly than CRRT [33,40-
42]. In one study the cost of CRRT was more than double 
of that of IRRT [42]. Of course, analyses performed in 
single health service delivery settings may be biased 
because data may be context speciﬁ c. A recent 
transcontinental multicenter and multinational analysis 
in the context of the Beginning and Ending Supportive 
Th erapy for the Kidney study, however, evaluated cost in 
the intensive care unit (ICU) and revealed substantial 
diﬀ erences in cost by region, but in addition indicated a 
higher trend for global cost of CRRT for most of the 
locations where data were collected. Th e median 
diﬀ erence was US$289.6 per day in disfavor of CRRT 
[43]. Th e main diﬀ erences could be attributed to ﬂ uid 
replacement and the extracorporeal circuit; reducing the 
substitution volume to <25 ml/minute/kg, as recently 
suggested [44], diminished cost only by US$67.2 per day 
[43]. Although the general trend for the median cost of 
nursing staﬀ  was slightly in disfavor of IRRT, results were 
highly variable and depended on whether or not extra 
staﬀ  were deployed for the application of CRRT. Overall, 
dialysate and replacement ﬂ uid costs and extracorporeal 
circuit costs were in favor of IRRT worldwide, irres pec-
tive of the continent where the analysis was undertaken.
Overall, however, the data from all these studies taken 
together point to a cost advantage for IRRT. Of note, 
although the Beginning and Ending Supportive Th erapy 
for the Kidney study is an important step forward as it 
contains comparative analysis from 23 countries and ﬁ ve 
continents, assessments were center-based rather than 
patient-based. Cost prediction was for that matter 
focused on general perception rather than on individual 
data. Further analyses might include patient-to-patient 
assessments of real costs comprising relative work load 
and related expenditures.
Restriction of bleeding complications
Owing to the continuous contact of the ﬁ lter with blood, 
CRRT necessitates appropriate anticoagulation 24 hours 
per day – increasing the bleeding risk, especially in those 
who had a trauma or recent surgery or who suﬀ er from 
medical diseases prone to bleeding. Th is drawback can be 
solved by regional citrate anticoagulation [45,46], but this 
option depends on skilled personnel and any mistake or 
technical problem may have grave consequences, such as 
life-threatening hypocalcemia. In units with dedicated 
personnel, however, outcomes with citrate might be 
beneﬁ cial [47]. Owing to high diﬀ usive clearance, citrate 
anti coagulation is more easily applicable and less 
dangerous in IRRT as compared with in CRRT.
In a large RCT, bleeding complications were more 
frequent in the CRRT group and were the major reason 
for switching modalities from CRRT to IRRT [11]. With 
IRRT, anticoagulation may be omitted or minimized, and 
does not take place all day long. Kumar and colleagues 
found that patients on IRRT versus those on CRRT had 
less need for anticoagulation, and that a much larger pro-
por tion of patients could be treated without coagulation 
at all [48]. Additionally, and in spite of continuous 
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anti coagulation, ﬁ lter clotting tends to occur more 
frequently with CRRT than with IRRT [14].
Small solute removal in acute life-threatening conditions
Although in general the adequacy of IRRT and CRRT 
depends on the actual conditions under which the 
modali ties are applied, IRRT has a more eﬃ  cient imme-
diate eﬀ ect than CRRT when small water-soluble 
compounds are to be removed in an acute life-
threatening condition because of the high blood and 
dialysate ﬂ ows that can be achieved, resulting in a 
superior clearance and mass transfer per time unit [49]. 
Th is is highly relevant for severe hyper kalemia, especially 
in the initiation phase of AKI and in patients with 
rhabdomyolysis, in whom potassium release from the 
compressed and necrotized muscle may last for several 
days [50]. For that reason IRRT has been used extensively 
in the aftermath of disasters [51,52]. Other speciﬁ c 
indications proﬁ ting from high solute removal are tumor 
lysis syndrome and certain cases of poisoning.
Specifi c patient populations benefi ting from intermittent 
renal replacement therapy
IRRT might be a useful strategy in any patient with 
bleeding or bleeding risk, including those after recent 
surgery, and is indicated for the acute treatment of hyper-
kalemia and rhabdomyolysis. For the global ICU popu-
lation, there seems to be no clinical preference for either 
one of both IRRT or CRRT, but assets in favor of IRRT 
are its practical ﬂ exibility and cost-eﬀ ectiveness.
Conclusions – towards slow long-extended daily 
dialysis
Since both CRRT and IRRT are perfectly acceptable for 
clinical therapeutic use, by extrapolation the same might 
also apply to all intermediary solutions that lie in 
between.
SLEDD is a hybrid therapy, oﬀ ering advantages of both 
CRRT and IRRT [3,48,53], combining protracted treat-
ment with an intermittent time scheme, usually applying 
IRRT machines, and representing a high-tech return to 
the roots of dialysis as applied in the early days by Kolﬀ  
[1]. Th e major advantages of this approach are the 
ﬂ exibility of the system, the reduced costs as compared 
with CRRT, and the possibilities for application with low 
or even absent anticoagulation [54].
Comparative studies between SLEDD and CRRT 
resulted in similar indices of adequacy and a similar 
hemo dynamic response [3,48,55,56]. In one study of 16 
patients, acidosis was slightly higher and blood pressure 
was lower with SLEDD, but only at 2 hours after the start 
of treatment [57,58]. Of note, blood pressure was 
nonsigniﬁ cantly lower by some 8 mmHg with SLEDD 
than before treatment onset. Th e appli cation of the 
Genius® batch dialysis system (Fresenius Medical Care, 
Bad Homburg, Germany), whereby dialysate is warmed 
only before the start of the session and allowed 
subsequently to cool slowly, may have an extra positive 
hemodynamic impact [59]. Flexi bility lies both in the 
duration of and in the intensity of the treatment. In 
SLEDD, the blood ﬂ ow, the dialysate ﬂ ow and often also 
the rate of ultraﬁ ltration can be tailored to the actual 
needs of the patient – in contrast to CRRT, where, due to 
technical constraints, in practice the maximal intensity is 
limited. SLEDD can thus be performed as a low-intensive 
and prolonged treatment but also as a shorter highly 
intensive modality, for each option with the same 
machine.
Because of the adequate removal capacity, the possi-
bility that drugs are more eﬀ ectively cleared than with 
traditional short IRRT should be taken into account, so 
that the classically recommended drug doses might be 
not applicable [60,61]; especially, antibiotics might be 
aﬀ ected substantially – if possible, concentrations should 
be measured regularly for therapeutic monitoring. Th e 
same might apply, however, for CRRT [62-64].
Most of these conclusions are extrapolated from com-
pari sons between IRRT and CRRT (see above) with 
SLEDD as an intermediate strategy. Controlled outcome 
trials comparing SLEDD with the more traditional 
approaches in large populations are to the best of our 
knowledge lacking at this moment. Although such a 
comparison was not the primary aim of the study, 
however, indirect evidence from the Veterans Admins-
tration trial suggests SLEDD to yield similar out comes to 
CRRT and IRRT [30]. Further studies exploring potential 
beneﬁ ts of each modality are awaited. In view of the 
heterogeneity of the ICU population and the strong 
inﬂ uence of center experience with individual modalities, 
however, it is unlikely that a ﬁ nal answer will ever be 
obtained.
In summary, CRRT and IRRT are equivalent dialysis 
strategies regarding outcome for the ICU patient with 
AKI, with a few exceptions for speciﬁ c problems that are 
a direct indication for either one or the other strategy. 
Assets evoked in the present article in favor of CRRT are 
its potential for more ﬂ uid removal in severely overloaded 
patients, its potential – however hardly proven – for 
better hemo dynamic stability in severely unstable 
patients, and its better tolerability in combined acute 
liver and kidney failure and in acute brain injury. IRRT is 
more practical, ﬂ exible and cost-eﬀ ective, allows the 
clinician to dis con tinue or to minimize anticoagulation 
with bleeding risks, and removes small solutes such as 
potassium more eﬃ  ciently in acute life-threatening 
conditions. SLEDD is a hybrid therapy combining most 
of the advantages of both options. All these options 
should not be considered as com petitors, but rather as 
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alternatives that may be switched in the same patient 
depending on his/her condition and the ad hoc possi-
bilities at a given moment in a given unit. From the 
practical point of view, among these modalities, SLEDD 
seems to oﬀ er the highest ﬂ exibility to tailor treatment 
according to the individual needs of the patient.
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